Literature DB >> 26733264

Otoprotective properties of 6α-methylprednisolone-loaded nanoparticles against cisplatin: In vitro and in vivo correlation.

Sergio Martín-Saldaña1, Raquel Palao-Suay2, Almudena Trinidad1, María Rosa Aguilar3, Rafael Ramírez-Camacho4, Julio San Román2.   

Abstract

6α-Methylprednisolone-loaded surfactant-free nanoparticles have been developed to palliate cisplatin ototoxicity. Nanoparticles were based on two different amphiphilic pseudo-block copolymers obtained by free radical polymerization and based on N-vinyl pyrrolidone and a methacrylic derivative of α-tocopheryl succinate or α-tocopherol. Copolymers formed spherical nanoparticles by nanoprecipitation in aqueous media that were able to encapsulate 6α-methylprednisolone in their inner core. The obtained nanovehicles were tested in vitro using HEI-OC1 cells and in vivo in a murine model. Unloaded nanoparticles were not able to significantly reduce the cisplatin ototoxicity. Loaded nanoparticles reduced cisplatin-ototoxicity in vitro being more active those based on the methacrylic derivative of vitamin E, due to their higher encapsulation efficiency. This formulation was able to protect hair cells in the base of the cochlea, having a positive effect in the highest frequencies tested in a murine model. A good correlation between the in vitro and the in vivo experiments was found. FROM THE CLINICAL EDITOR: Cisplatin is a commonly used chemotherapeutic agent against many cancers clinically. However, one of the significant side-effects remains ototoxicity. Here, the authors presented their data on using 6α-methylprednisolone-loaded nanoparticles in the reduction of ototoxicity in in-vitro and in-vivo experiments. Early promising results should enable further refinement of adopting this new approach in future experiments.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cisplatin; HEI-OC1; Nanoparticles; Otoprotection; Vitamin E; α-Tocopheryl succinate

Mesh:

Substances:

Year:  2015        PMID: 26733264     DOI: 10.1016/j.nano.2015.12.367

Source DB:  PubMed          Journal:  Nanomedicine        ISSN: 1549-9634            Impact factor:   5.307


  7 in total

1.  Comparison of the protective efficacy between intratympanic dexamethasone and resveratrol treatments against cisplatin-induced ototoxicity: an experimental study.

Authors:  Gökçe Simsek; Burak Mustafa Taş; Nuray Bayar Muluk; Musa Azman; Rahmi Kılıç
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-09-17       Impact factor: 2.503

2.  Toxicology study for magnetic injection of prednisolone into the rat cochlea.

Authors:  M Shimoji; B Ramaswamy; M I Shukoor; P Benhal; A Broda; S Kulkarni; P Malik; B McCaffrey; J-F Lafond; A Nacev; I N Weinberg; B Shapiro; D A Depireux
Journal:  Eur J Pharm Sci       Date:  2018-06-19       Impact factor: 4.384

3.  Nanomedicine strategy for optimizing delivery to outer hair cells by surface-modified poly(lactic/glycolic acid) nanoparticles with hydrophilic molecules.

Authors:  Xingxing Wen; Shan Ding; Hui Cai; Junyi Wang; Lu Wen; Fan Yang; Gang Chen
Journal:  Int J Nanomedicine       Date:  2016-11-10

Review 4.  Nanomedicine for Inner Ear Diseases: A Review of Recent In Vivo Studies.

Authors:  Dong-Kee Kim
Journal:  Biomed Res Int       Date:  2017-10-10       Impact factor: 3.411

Review 5.  Current Strategies to Combat Cisplatin-Induced Ototoxicity.

Authors:  Dehong Yu; Jiayi Gu; Yuming Chen; Wen Kang; Xueling Wang; Hao Wu
Journal:  Front Pharmacol       Date:  2020-07-03       Impact factor: 5.810

Review 6.  The Use of Nanoparticles in Otoprotection.

Authors:  Maurizio Barbara; Valerio Margani; Edoardo Covelli; Chiara Filippi; Luigi Volpini; Ola M El-Borady; Maged El-Kemary; Saad Elzayat; Haitham H Elfarargy
Journal:  Front Neurol       Date:  2022-06-29       Impact factor: 4.086

7.  Solid Lipid Nanoparticles Loaded with Glucocorticoids Protect Auditory Cells from Cisplatin-Induced Ototoxicity.

Authors:  Blanca Cervantes; Lide Arana; Silvia Murillo-Cuesta; Marina Bruno; Itziar Alkorta; Isabel Varela-Nieto
Journal:  J Clin Med       Date:  2019-09-14       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.